<DOC>
	<DOCNO>NCT00777842</DOCNO>
	<brief_summary>The GTX™ Drug Eluting Coronary Stent System intend treatment patient lesion coronary artery .</brief_summary>
	<brief_title>Evaluation GTX™ 5126 DES Coronary Stent System Treatment Patients With Lesion Coronary Artery</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Key Patient discrete de novo lesion coronary artery symptomatic ischemic heart disease Planned treatment one lesion single stent Denovo type A , B1 lesion Reference diameter 3.0 3.5mm lesion length 5 16mm Key Diabetic ( HbA1C &gt; 6.0 ) Platelet count &lt; 100000 cells/mm3 &gt; 700000 cells/mm3 ; WBC &lt; 3000 cells/mm3 ; hemoglobin &lt; 10 g/dl Renal dysfunction creatinine &gt; 2.0 mg/dl Patient know predilatation ejection fraction ( EF ) less forty five ( &lt; 45 % ) Myocardial infarction ( MI ) less 3 month prior intervention Patient type B2 , C lesion Reference artery diameter &lt; 3.0 &gt; 3.6 mm Target lesion length &lt; 5mm &gt; 16 mm Other stenosis &gt; 50 % target vessel Known hypersensitivity contraindication aspirin , clopidogrel , ticlopidine , cobalt chromium , sensitivity contrast agent , opinion investigator , adequately premedicated .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>